RWJ 52353

Discontinued Product

3935 has been discontinued.

View all Adrenergic &alpha;<sub>2</sub> Receptors products.
说明: α2D agonist
化学名: 5-(6,7-Dihydrobenzo[b]thien-4-yl-1H-imidazole hydrochloride
纯度: ≥98% (HPLC)
说明书
引用文献
评论
文献 (2)

生物活性 for RWJ 52353

RWJ 52353 is a agonist of the α2D adrenergic receptor (Ki values are 1.5, 254, 443 and 621 nM for α2D, α2A, α1 and α2B adrenergic receptors respectively).

技术数据 for RWJ 52353

分子量 202.28
公式 C11H10N2S
储存 Store at +4°C
纯度 ≥98% (HPLC)
CAS Number 245744-10-9
PubChem ID 71752148
InChI Key LIHWQUZNTRDJFW-UHFFFAOYSA-N
Smiles C1(SC=C2)=C2C(C3=CN=CN3)=CCC1.Cl

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 Adrenergic α2 Receptor Agonists

关键词: RWJ 52353, RWJ 52353 supplier, RWJ52353, agonists, alpha2D, a2d, α2d, adrenergic, receptors, adrenoceptors, Adrenergic, Alpha-2, Receptors, 3935, Tocris Bioscience

篇 RWJ 52353 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 RWJ 52353 的引用文献。

RWJ 52353 的评论

目前没有该产品的评论。 Be the first to review RWJ 52353 and earn rewards!

Have you used RWJ 52353?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.